News & Updates
Filter by Specialty:
Tolebrutinib reduces disability accumulation in relapsing MS
Treatment with tolebrutinib results in a clear reduction in disability accumulation in patients with relapsing multiple sclerosis (MS) compared with teriflunomide despite no difference in relapses, according to the findings of the GEMINI 1 and 2 trials presented at AAN 2025.
Tolebrutinib reduces disability accumulation in relapsing MS
21 Apr 2025
Consistent benefits with lecanemab seen in Clarity AD Asian cohort
In the treatment of early Alzheimer’s disease (AD), lecanemab is as safe and efficacious in Asian patients as in the wider Clarity AD population, slowing cognitive decline and reducing amyloid levels in the brain with manageable risks.
Consistent benefits with lecanemab seen in Clarity AD Asian cohort
19 Apr 2025
X-TOLE OLE interim analysis shows long-term efficacy of novel agent for focal epilepsy
Interim data from the ongoing 7-year open-label extension (OLE) of the phase IIb X-TOLE study reflect the long-term efficacy and safety of azetukalner, an investigational, potent Kv7 potassium channel opener, for the treatment of adults with focal epilepsy.
